Evidence mapPaperPMID 34477201Full record

ArticleBriefings in bioinformatics2022

Machine learning methods, databases and tools for drug combination prediction.

Lianlian Wu, Yuqi Wen, Dongjin Leng, Qinglong Zhang, Chong Dai, Zhongming Wang, Ziqi Liu, Bowei Yan, Yixin Zhang, Jing Wang and 2 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Scaling up drug combination surface prediction.Briefings in bioinformatics · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lianlian WuAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.ORCID 0000-0002-9611-4488
Yuqi WenBeijing Institute of Radiation Medicine, Beijing, China.
Dongjin LengBeijing Institute of Radiation Medicine, Beijing, China.
Qinglong ZhangBeijing Institute of Radiation Medicine, Beijing, China.
Chong DaiCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Zhongming WangAcademy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Ziqi LiuState Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, AMMS, Beijing, China.
Bowei YanBeijing Institute of Radiation Medicine, Beijing, China.
Yixin ZhangBeijing Institute of Radiation Medicine, Beijing, China.
Jing WangSchool of Medicine, Tsinghua University, Beijing, China.
Song HeBeijing Institute of Radiation Medicine, Beijing, China.ORCID 0000-0002-4136-6151
Xiaochen BoBeijing Institute of Radiation Medicine, Beijing, China.ORCID 0000-0003-1911-7922

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination therapy has shown an obvious efficacy on complex diseases and can greatly reduce the development of drug resistance. However, even with high-throughput screens, experimental methods are insufficient to explore novel drug combinations. In order to reduce the search space of drug combinations, there is an urgent need to develop more efficient computational methods to predict novel drug combinations. In recent decades, more and more machine learning (ML) algorithms have been applied to improve the predictive performance. The object of this study is to introduce and discuss the recent applications of ML methods and the widely used databases in drug combination prediction. In this study, we first describe the concept and controversy of synergism between drug combinations. Then, we investigate various publicly available data resources and tools for prediction tasks. Next, ML methods including classic ML and deep learning methods applied in drug combination prediction are introduced. Finally, we summarize the challenges to ML methods in prediction tasks and provide a discussion on future work.

Indexed as

AlgorithmsMachine LearningDatabases, FactualDrug CombinationsDrug InteractionsDrug Combinationsdeep learningdrug combination databasedrug combination predictionmachine learningsynergy

Identifiers

PMID34477201
PMCPMC8769702

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.